Recipharm invests EUR 2.6 million in Kaysersberg facility
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR 2.6 million investment for additional manufacturing capacity to support increased demand into its Kaysersberg facility.
This investment in the Kaysersberg facility, located in the Alsace region of France, will add additional capacity and capabilities for the company’s customers, as the company continues to secure new business for the future.
This latest investment is part of Recipharm’s phased expansion plan for the facility. Yves Buelens, General Manager at the Kaysersberg facility, said: “It’s great to see more investment into our facility. Our sustained growth over the last few years is testament to our talented and passionate team. We continue to look for new ways to develop our offering and implement our continued growth plan, which will naturally bring more employment opportunities to the region.”
Recipharm in Kaysersberg is one of the company’s sterile manufacturing facilities. It specialises in producing sterile liquids for therapeutic areas including eye care and ear drops.
The facility has been inspected and approved by multiple regulatory agencies across the globe. It also holds a number of approvals for its environmental management systems and occupational health and safety management systems.
Yves Buelens, General Manager, firstname.lastname@example.org, +33 607 797 901
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com